Skip to content

Prime Medicine PRME Deferred Revenue

Deferred Revenue at other companies

Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$630K-97.0%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$15.34M+408%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$304K-99.6%
Regenxbio logo
RegenxbioRGNX
$5.92M-56.4%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$116.04M+159%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$2M-52.9%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's deferred revenue?
Prime Medicine (PRME) reported deferred revenue of $7.32M in Q1 2026.
How has Prime Medicine's deferred revenue changed year-over-year?
Prime Medicine's deferred revenue decreased by 10.9% year-over-year, from $8.21M to $7.32M.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.